AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00324610
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00113503
Drug: Azathioprine weight-based dose
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00113503
Drug: Azathioprine individualised dose
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04545385
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT02196129
Drug: Sinbaro-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1cc administered to site of pain(ashi acupoints), once and once only before any other intervention/if pain in both low back and extermities, the site of most pain
Trial: NCT02196129
Drug: Hwangryun
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1cc administered to site of pain(ashi acupoints), once and once only before any other intervention/if pain in both low back and extermities, the site of most pain
Trial: NCT02197156
Drug: 10 mg HC-ER
RxNorm normalized name: hydrocortisone 10 MG/ML [Aquanil HC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT02197156
Drug: 30 mg HC-ER
RxNorm normalized name: Touro HC 5 MG / 575 MG Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT02197156
Drug: 10 mg HC / 325 mg APAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT02197156
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT00412620
Drug: ABT-925
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00412620
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03561883
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT03561883
Drug: Standard-dose PPIs QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: background therapy
Trial: NCT02276677
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, intranasal
Trial: NCT01369433
Drug: Tivozanib + capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 1.5 mg of tivozanib once daily for 2 weeks beginning on Day 1, followed by 1 week off. Subjects will receive Capecitabine (Xeloda®) 825 mg/m2 or 1000 mg/m² or 1250 mg/m² oral twice daily. Subjects will receive capecitabine twice daily for 2 weeks beginning on Day 1, followed by 1 week off.
Trial: NCT03163966
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral Methotrexate tablets
Trial: NCT03163966
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral CR6086 Placebo capsules
Trial: NCT03805399
Drug: Pyrotinib with Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: If patients were LAR subtype with HER2 gene activated mutation, she would receive pyrotinib(EGFR-TKI) 400mg qd and capecitabine 1000mg/m2 bid (d1-d14)
Trial: NCT03805399
Drug: BLIS with anti-VEGFR included therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If patients were BLIS subtype and did not have a BRCA gene pathogenic mutation , she will receive:~E2: apatinib 250mg qd continuously combined with VP-16 50mg qd (three week on one week off); E3: famitinib 20mg qd continuously combined with VP-16 50mg qd (three week on one week off); E4: BP102 10mg/kg d1,d15 combined with nab-paclitaxel 100mg d1,d8,d,15; q4w
Trial: NCT03805399
Drug: MES with anti-VEGFR included therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If patients were MES subtype and without PI3K/AKT pathway activation,she will receive famitinib 20mg qd continuously combined with VP-16 50mg qd (three week on one week off).
Trial: NCT00324155
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous solution; intravenous; 0 mg; one dose every 3 weeks for 10 weeks then one dose every 12 weeks starting at Week 24; until disease progression, unacceptable toxicity or withdrawal of consent
Trial: NCT03314025
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peri-operative therapy of a Placebo oral capsule daily for a total of 7 days.
Trial: NCT00009997
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00009997
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00049569
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT
Trial: NCT00049569
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00049569
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00049569
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00049569
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IT
Trial: NCT01756703
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 8 weeks
Trial: NCT00888745
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and subcutaneous ascending dose
Trial: NCT00888745
Drug: PRO283698
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and subcutaneous ascending dose
Trial: NCT00315549
Drug: Telithromycin
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002791
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00117819
Drug: [123I]ß CIT and SPECT imaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To assess \[123I\]ß CIT and SPECT imaging
Trial: NCT04525820
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient receives a single dose of a placebo solution
Trial: NCT03274817
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to group C will receive placebo tablets, which will be matched to the Lexapro and the Effexor XR as far as possible, and will also be administered on a once daily schedule at baseline.
Trial: NCT00399750
Drug: fluoropyrimidine
RxNorm normalized name: Fluoropyrimidine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03137537
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procedure prescribed to compare the active effect of a medicine.
Trial: NCT03218592
Drug: Truvada Pill
RxNorm normalized name: Truvada Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weeklySubjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
Trial: NCT03338010
Drug: LY2963016
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03338010
Drug: Lantus®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01601730
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching oral placebo capsules as control (Treatment 1: Modafinil 0 + Escitalopram 0).
Trial: NCT03210766
Drug: THC/CBD
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02098772
Drug: Custodiol-N
RxNorm normalized name: N-ethylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
Trial: NCT02098772
Drug: Custodiol
RxNorm normalized name: CUSTODIOL HTK SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
Trial: NCT00262925
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or orally
Trial: NCT00262925
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00262925
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02504164
Drug: No premedication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No premedication before sedation for endoscopic submucosal dissection
Trial: NCT02105090
Drug: Anesthetics, Local
RxNorm normalized name: ANESTHETICS, LOCAL
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03040531
Drug: Alendronate Oral Tablet
RxNorm normalized name: alendronate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mg/week in tablets
Trial: NCT02760888
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Women will receive oral Diclofenac 100mg 1 hour before the procedure
Trial: NCT02760888
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women will receive a Placebo 1 hour before the procedure
Trial: NCT04659109
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration
Trial: NCT00097695
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection, matched to study drug Single dose: 3 mL
Trial: NCT01508936
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses).
Trial: NCT03091439
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received an antibiotic consistent with standard of care (SOC) for osteomyelitis based on Investigator judgment. The duration of treatment was 4-6 weeks.
Trial: NCT03229499
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablet
Trial: NCT02698293
Drug: Vitamin D3 cholecalciferol)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.
Trial: NCT01214278
Drug: GArTG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA+DHA as rTGs from fish-oil in gastric acid resistant (coated) capsules (GArTG); 4 capsules per day; 2016 mg n-3 fatty acids (1008 mg EPA and 672 mg DHA)
Trial: NCT01214278
Drug: EE
RxNorm normalized name: Beer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA+DHA as ethylesters (EE) from fish-oil uncoated capsules (4 per day); 2016 mg n-3 fatty acids (1008 mg EPA and 672 mg DHA)
Trial: NCT02696798
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01860989
Drug: KAE609
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KAE609 75mg single dose
Trial: NCT01860989
Drug: KAE609
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KAE609 150mg single dose
Trial: NCT01860989
Drug: KAE609
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KAE609 225mg single dose
Trial: NCT01860989
Drug: KAE609
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KAE609 300mg single dose
Trial: NCT04184141
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo candy
Trial: NCT01584934
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment is started and continued for 6 weeks at patient's home. Patients receive 3 g/night during the first week and 4.5 g/night during the second week. After the second week, patients have their dose increased to 6 g/night during 6 weeks. A washout period of 4 weeks is installed to withdraw from treatment. Patients receive 4.5 g/night for 1 week, followed by 3 g/night for 1 week. The next 2 weeks, patients are not treated.
Trial: NCT02787278
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same dosage of SP8203. Placebo will be intravenously administered twice daily (intervals of 12 hours)
Trial: NCT02218164
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug administration will be on an outpatient basis. Capecitabine will be administered at an initial dose of 800 mg/m\^2 by mouth twice daily on days 1-14 of a 21 day cycle with days 15-21 off. This cycle will be repeated every 21 days during the study for a maximum of 9 cycles as tolerated. Administration via feeding tube in patients unable to swallow is permitted.
Trial: NCT02251847
Drug: Rosuvastatin/Ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 5mg
Trial: NCT00513214
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Part 1, Single IV infusion at one of six dose levels (mg/kg).~* Part 2, Single SC injection at one of three dose levels (mg/kg).~* Part 3, Three biweekly SC injections at one of two dose levels (mg/kg).
Trial: NCT01691248
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet once daily from the start (+/- 2 days) of condition (prior to transplantation) or at the time of Fluoroquinolone initiation. Treatment will continue until 7 days after either neutrophil engraftment or the completion of any Fluoroquinolone antibiotic regimen (whichever occurs later).~Treatment will stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administered or neutrophil engraftment extends beyond 40 days.
Trial: NCT04355468
Drug: Opioid Free Anaesthesia
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before the induction of general anesthesia, a single-shot thoracic paravertebral block (ThPVB) was performed at the Th3-Th4 level. An insulated needle was used, connected to a peripheral nerve stimulator. 0.5% bupivacaine (0.3 ml∙kg-1) was then injected after a negative aspiration test. The efficacy of the blockade was checked after 20 min on both sides of the thorax with a plastic ampoule of saline. A difference in the sensation of cold between the sides of the thorax was assumed to indicate an effective block. Afterwards a continuous intravenous infusion of lidocaine and ketamine was started:~1. immediately after anesthesia induction, lidocaine was administered as an i.v. bolus at a dose of 1.5 mg∙kg-1 and ketamine in an i.v. bolus of 0.35 mg∙kg-1;~2. followed by an infusion of lidocaine 2.0 mg∙kg-1∙h-1 for 2 hours, continued at a dose of 1.2 mg∙kg-1∙h-1, and ketamine infusion 0.2 mg∙kg-1∙h-1 for 2 hours, continued at a dose of 0.12 mg∙kg-1∙h-1.
Trial: NCT01669538
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00379340
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00379340
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01265056
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar Pill is administered similar to the protocol used for the investigational drug.
Trial: NCT02580630
Drug: Ultrasound guided injection with Glucocorticosteroid
RxNorm normalized name: Marcaine with Epinephrine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound guided injection in Kagers triangle underneath the thickest part of the achilles tendon with 1ml Lidocain 5 mg/ml and 1 ml methylprednisolone 40mg/ml. Injection is given every months until the tendon pain is markedly reduced (VAS morning pain: 0-20, and VAS training pain: 0-40, and Global recovery rating scale (-5 to +5) is +3 to +5 ). (max 3 injections).
Trial: NCT02580630
Drug: Ultrasound guided injection with local anaestethic
RxNorm normalized name: Marcaine with Epinephrine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound guided injection in Kagers triangle underneath the thickest part of the achilles tendon with 1ml Lidocain 5 mg/ml and 1 ml of intralipid (for blinding). Injection is given every months until the tendon pain is markedly reduced (VAS morning pain: 0-20, and VAS training pain: 0-40, and Global recovery rating scale (-5 to +5) is +3 to +5 ). (max 3 injections).
Trial: NCT02518113
Drug: LY3039478
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02518113
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00861809
Drug: GSK962040 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg
Trial: NCT00861809
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo comparator
Trial: NCT00861809
Drug: GSK962040 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg
Trial: NCT00861809
Drug: GSK962040 1250 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg
Trial: NCT03443778
Drug: Nacl 0,9 %
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable Solution
Trial: NCT01918384
Drug: NPC-14
RxNorm normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPC-14 will be administrated as following steps. The dose of NPC-14 will be calculated and adjusted by a non-blinded medical doctor and/or a non-blinded pharmacist.~* An initial dose of NPC-14 will be half of that calculated by distribution volume：Vd based on patient age for safety reason.~* After the initial administration, the dose of NPC-14 will be adjusted and maintained by actual Vd, therapeutic drug monitoring of peak serum levels of NPC-14
Trial: NCT01918384
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose will be adjusted by volume of distribution (Vd) of patients in accordance with the NPC-14 dose regimen
Trial: NCT02841774
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg daily (Weeks 2 - 14)
Trial: NCT02841774
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20mg daily (Weeks 2 - 14); at Week 6, if AST, AST, and CK \<+1.5 x ULN, and LDL-c is \>60 and decreased by less than 25% compared with week 2, then dose will be increased to rosuvastatin 40mg daily
Trial: NCT00990886
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily for 12 weeks
Trial: NCT01980940
Drug: Etoricoxib 75 mg 4% DMSO Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 75 mg 4% DMSO gel applied topically.
Trial: NCT01980940
Drug: Etoricoxib 75 mg 4% PG Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 75 4% PG gel applied topically.
Trial: NCT01980940
Drug: Etoricoxib 150 mg 4% DMSO Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 150 mg 4% DMSO gel applied topically.
Trial: NCT01980940
Drug: Etoricoxib 150 mg 4% PG Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 150 mg 4% PG gel applied topically.
Trial: NCT01980940
Drug: Etoricoxib 163 mg 4% DMSO gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 163 mg 4% DMSO gel applied topically
Trial: NCT01980940
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel applied topically.
Trial: NCT01980940
Drug: Etoricoxib 50 mg 4% DMSO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 50 mg 4% DMSO gel applied topically.
Trial: NCT01980940
Drug: Matching Placebo to Etoricoxib 50 mg 4% DMSO Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo to Etoricoxib 50 mg 4% DMSO gel applied topically.
Trial: NCT00987545
Drug: QAX576
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QAX576 injection
Trial: NCT00987545
Drug: QAX576 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to QAX576 injection
Trial: NCT01857856
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: eplerenone (inspra; pfizer) one tablet (50mg standard dosis; 25mg reduced dosis) per day
Trial: NCT00876421
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo / 12 weeks
Trial: NCT03962829
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy participants administrate one capsule of placebo (containing lactose)
Trial: NCT00146471
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500-2000 mg daily add-on or Placebo Diazepam as needed
Trial: NCT01117610
Drug: Placebo (one of medication)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients in Group C will receive none of medication preoperatively and intraoperatively